OXFORD, UK--Incyte Pharmaceuticals and Oxford GlycoSciences announced the second of three new programs the companies have developed to integrate gene and protein expression data. PharmacoProgram applies proteomics technology to study compound efficacy and safety. Customers will be able to purchase multiyear access to PharmacoProgram along with a predetermined number of customer-driven gene and expression analysis experiments.